- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04488081
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID)
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients
Study Overview
Status
Conditions
Detailed Description
This platform trial will provide access to repurposed and investigational agents for critically ill patients infected with SARS-CoV-2 who have severe or life-threatening COVID-19. The main focus of this trial is a platform study for identifying effective agents for the treatment of COVID-19. Any critically ill patient with known or presumed COVID-19 will be automatically entered into the screening phase of the trial until SARS-CoV-2 infection is confirmed. Basic data will be assembled for each patient (such as ventilatory status and survival). If interested in the therapeutic portion of the trial, potential participants will be asked to sign a consent form describing the backbone treatment and the two specific investigational agent arms to which they may be randomized. The primary endpoints will be time to recover to a durable level 4 (or less) on the WHO COVID-19 ordinal scale for clinical improvement and time to mortality (death). For this trial, a durable level 4 is defined as at least 48 hours at COVID level 4 or less (nasal prongs oxygen) without returning to high flow oxygen or intubation. Acute care facility resource utilization will be automatically calculated (total length of stay in a critical care setting, days intubated, and survival). Any change in status, including intubation, extubation, death or discharge, will be recorded and verified by the attending physician.
Patients will be evaluated based on their initial status (ventilation at entry vs. high flow oxygen). Exploratory biomarkers will be evaluated over time (ARDS phenotypes and other proposed markers) to facilitate clinical learning. A maximum of two investigational arms may be open at a time. The anticipated accrual will be 50 patients per week. The maximum number of participants assigned to an arm without graduation will be 125 patients. Agents can be dropped for futility after enrollment of 40 patients. As the trial proceeds and a better understanding of the underlying mechanisms of the COVID-19 illness emerges, expanded biomarker and data collection can be added as needed to further elucidate how agents are or are not working. The study design features comparison of investigational agent efficacy using a Bayesian design, which will allow the detection of strong efficacy signals with the fewest possible patients. Initially the control will be patients given current standard of care (supportive care for ARDS, including lung protective ventilation and remdesivir and dexamethasone as backbone therapy). As other treatments (for example, anticoagulation) become part of standard supportive care across sites, these will be added to the backbone therapy. If an agent meets the threshold for graduation the company leadership will be informed as will the FDA. The arm with the graduated agent will cease to enroll, allowing a new arm with a different investigational agent to be added.
Every trial participant will have blood collected at trial enrollment, day 3, and day 7 for pre-specified biomarker and DNA and RNA analysis. Additional biomarkers can be added as the trial proceeds. Patient outcomes will also be evaluated on the basis of whether patients are ventilated initially or not.
Observational Component:
Initially, all COVID-19 confirmed patients who started high-flow oxygen (WHO COVID-19 level 5; ≥6L oxygen by nasal prongs or mask) were entered in an Observational Component which collected data via extraction of medical records. Patients in this Observational Component also had their daily COVID status and drug administration form CRFs completed. An expanded Observational Study will replace the original Observational Component. The expanded observational study (Supplement 1) will collect blood sample(s) and clinical data from ARDS and AHRF patients (including COVID ARDS patients) to test the feasibility of quantifying a set of biomarkers that will allow each patient to be classified into either a hyper-inflammatory or hypo-inflammatory subtype in real time. If treatment of these critically ill ICU patients is to be guided by subtype classification, it is essential that the operational time for classification is as quick as possible.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Paul Henderson, PhD
- Phone Number: 1-925-570-1615
- Email: p.henderson@quantumleaphealth.org
Study Contact Backup
- Name: Karyn DiGiorgio, MS
- Phone Number: 1-415-307-1539
- Email: karyn.digiorgio@quantumleaphealth.org
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Valerie Caterinicchia, RN, BSN
- Phone Number: 205-934-5367
- Email: val7@uab.edu
-
Principal Investigator:
- Derek Russell, MD
-
Sub-Investigator:
- Sheetal Gandotra, MD
-
-
California
-
Davis, California, United States, 95817
- Recruiting
- UC Davis Medical Center
-
Contact:
- Skyler Pearson
- Phone Number: 916-734-3867
- Email: sjpearson@ucdavis.edu
-
Principal Investigator:
- Timothy Albertson, MD
-
Irvine, California, United States, 92868
- Recruiting
- UC Irvine Medical Center
-
Contact:
- Richard Lee, MD
- Phone Number: 714-456-7890
- Email: richaral@hs.uci.edu
-
Long Beach, California, United States, 90806
- Recruiting
- Long Beach Memorial Medical Center
-
Contact:
- Daniel Blevins
- Phone Number: 562-760-6817
- Email: DBlevins@memorialcare.org
-
Principal Investigator:
- Fady Youseff, MD
-
Los Angeles, California, United States, 90033
- Recruiting
- University of Southern California
-
Contact:
- Melissa Ramos, BSN, RN
- Phone Number: 818-309-5542
- Email: Melissa.Ramos@med.usc.edu
-
Principal Investigator:
- Santhi Kumar, MD
-
Los Angeles, California, United States, 90027
- Recruiting
- Kaiser LAMC
-
Contact:
- Kenneth Wei, MD
- Phone Number: 323-783-8191
- Email: Kenneth.K.Wei@kp.org
-
Contact:
- David Silberstein, MD
- Phone Number: 3237831009
- Email: david.j.silberstein@kp.org
-
Newport Beach, California, United States, 92663
- Active, not recruiting
- Hoag Memorial Hospital Presbyterian
-
San Francisco, California, United States, 94115
- Recruiting
- University of California San Francisco (UCSF)
-
Contact:
- Phone Number: 877-827-3222
-
Principal Investigator:
- Kathleen Liu, MD
-
Principal Investigator:
- Carolyn Calfee, MD
-
Principal Investigator:
- Laura Esserman, MD
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado
-
Contact:
- Tessa Mcspadden
- Phone Number: 720-848-0609
- Email: tessa.mcspadden@ucdenver.edu
-
Principal Investigator:
- Ellen Burnham, MD
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale Cancer Center
-
Contact:
- Trisha Burello, MS
- Phone Number: 203-737-2848
- Email: trisha.burrello@yale.edu
-
Principal Investigator:
- Jonathan Koff, MD
-
Stamford, Connecticut, United States, 06904
- Active, not recruiting
- Stamford Health
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Recruiting
- Georgetown University
-
Contact:
- Amen Hamed
- Phone Number: 202-444-0895
- Email: amen.hamed@gunet.georgetown.edu
-
Principal Investigator:
- Nathan Cobb, MD
-
-
Florida
-
Coral Gables, Florida, United States, 33124
- Recruiting
- University of Miami
-
Contact:
- Karla L Escalona
- Email: kil19@med.miami.edu
-
Principal Investigator:
- Christopher P Jordan, MD
-
Gainesville, Florida, United States, 32608
- Active, not recruiting
- University of Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
Contact:
- Christine Spainhour, CCRC
- Phone Number: 404-778-7850
- Email: christine.spainhour@emory.edu
-
Principal Investigator:
- Sara Auld, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Completed
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Completed
- University of Iowa
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Active, not recruiting
- University of Michigan
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Corewell Health
-
Contact:
- Malik Khan, MD
- Phone Number: 866-989-7999
- Email: malik.khan@spectrumhealth.org
-
-
Missouri
-
Springfield, Missouri, United States, 65804
- Completed
- Mercy Hospital Springfield
-
-
Montana
-
Kalispell, Montana, United States, 59901
- Completed
- Kalispell Regional Medical Center
-
Kalispell, Montana, United States, 59901
- Completed
- Logan Health Medical Center
-
-
New Jersey
-
Mount Holly, New Jersey, United States, 08060
- Recruiting
- Virtua Mount Holly Hospital
-
Contact:
- Kristin Broderick
- Phone Number: 856-355-1225
- Email: KBroderick@virtua.org
-
Contact:
- Lissa Ferrant
- Email: LFerrant@virtua.org
-
Principal Investigator:
- Emillio Mazza, MD
-
Voorhees, New Jersey, United States, 08043
- Recruiting
- Virtua Voorhees Hospital
-
Principal Investigator:
- Emillio Mazza, MD
-
Contact:
- Lisa Ferrant
- Email: LFerrant@virtua.org
-
Contact:
- Kristin Broderick
- Email: KBroderick@virtua.org
-
-
New York
-
Bronx, New York, United States, 10461
- Completed
- Montefiore Medical Center
-
New York, New York, United States, 10032
- Completed
- Columbia University Medical Center
-
Rochester, New York, United States, 14642
- Completed
- University of Rochester Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Baptist Comprehensive Cancer Center
-
Contact:
- Angela Howell, MD
- Phone Number: 336-716-5440
- Email: anhowell@wakehealth.edu
-
Principal Investigator:
- D. Clark Files, MD
-
Principal Investigator:
- Karl Thomas, MD
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospital Cleveland Medical Center
-
Contact:
- Nisha Rao
- Email: Nisha.Rao@uhhospitals.org
-
Principal Investigator:
- Kenneth Remy, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania (U Penn)
-
Contact:
- Lauren Bayne
- Phone Number: 215-349-5398
- Email: Lauren.Bayne@uphs.upenn.edu
-
Principal Investigator:
- Nuala Meyer, MD, MS
-
Wynnewood, Pennsylvania, United States, 19096
- Recruiting
- Lankenau Medical Center (Mainline Health)
-
Contact:
- Ebuwa Erebor
- Email: EreborE@mlhs.org
-
Contact:
- Elliot Friedman, MD
- Phone Number: 484-476-2000
- Email: FriedmanE@mlhs.org
-
Wynnewood, Pennsylvania, United States, 19096
- Recruiting
- Main Line Health - Lankenau Medical Center
-
Contact:
- Christina Angelucci
- Email: AngelucciC@mlhs.org
-
Principal Investigator:
- Eliot Friedman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57109
- Recruiting
- Sanford Health
-
Contact:
- Allison Lutz
- Phone Number: 605-312-6971
- Email: Allison.Lutz@SanfordHealth.org
-
Principal Investigator:
- Paul Berger, MD
-
-
Texas
-
Edinburg, Texas, United States, 78539
- Recruiting
- DHR Health
-
Contact:
- Praveen Vijhani, MD
- Phone Number: 956-342-5413
- Email: p.vijhani@dhr-rgv.com
-
Contact:
- Lu Cantu
- Phone Number: 956-362-2396
- Email: l-cantu@dhr-rgv.com
-
Houston, Texas, United States, 77030
- Active, not recruiting
- University of Texas MD Anderson Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Active, not recruiting
- WVU Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
A. Male or Female, at least 18 years old
B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask delivery system) or intubated for the treatment of (established or presumed) COVID-19.
C. Informed consent provided by the patient, LAR or health care proxy.
D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2 infection prior to randomization.
Exclusion Criteria:
A. Pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization)
B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history.
C. Comfort measures only.
D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.
E. Resident for more than six months at a skilled nursing facility.
F. Estimated mortality greater than 50% over the next six months from underlying chronic conditions.
G. Time since requirement for high flow oxygen or ventilation greater than 5 days.
H. Anticipated transfer to another hospital which is not a study site within 72 hours.
I. Patients with either end-stage kidney disease or acute kidney injury who are on dialysis.
J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND.
K. On 3 or more vasopressors.
L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or unstable angina pectoris.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cenicriviroc + Standard of Care (CLOSED)
Subjects administered standard of care + cenicriviroc orally , loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
|
Experimental: Icatibant + Standard of Care (CLOSED)
Subjects administered standard of care + icatibant subcutaneously, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days.
All subsequent subjects received drug at 30 mg q8h x 6 days.
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days.
All subsequent subjects received drug at 30 mg q8h x 6 days.
Other Names:
|
Experimental: Apremilast + Standard of Care (CLOSED)
Subjects administered standard of care + apremilast orally , 30 mg bid × 14 days.
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
oral, 30 mg bid × 14 days.
Other Names:
|
Experimental: Dornase + Standard of Care (CLOSED)
For Non-intubated subjects: Subjects administered standard of care + dornase, 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first. For intubated subjects: Subjects administered standard of care + dornase, 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first. |
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first. For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first.
Other Names:
|
Experimental: Celecoxib/famotidine + Standard of Care (CLOSED)
Subjects administered standard of care + celecoxib/famotidine orally . Celecoxib, oral: 400 mg BID for 7 days. Famotidine, oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days. |
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Oral: 400 mg BID for 7 days.
Other Names:
Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
Other Names:
|
Experimental: IC14 + Standard of Care (CLOSED)
Subjects administered standard of care + IC14 intravenously , 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
|
Experimental: Narsoplimab + Standard of Care (CLOSED)
Subjects administered standard of care + narsoplimab dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
Other Names:
|
Experimental: Aviptadil + Standard of Care (CLOSED)
Subjects administered standard of care + aviptadil (inhalation via nebulizer), 100 µg three times (TID) daily for a maximum of 14 days
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
Other Names:
|
Experimental: Cyproheptadine + Standard of Care (CLOSED)
Subjects administered standard of care + cyproheptadine via 4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days.
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days.
If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days.
If the participant was discharged before completion of this dosing regimen the drug was not continued.
Other Names:
|
Experimental: Cyclosporine + Standard of Care (CLOSED)
Subjects administered standard of care + modified cyclosporine at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
Other Names:
|
Active Comparator: Control/Backbone - Remdesivir and Dexamethasone (CLOSED)
Participants randomized to the backbone control will be given standard of care (supportive care for ARDS, including remdesivir and, if needed, lung protective ventilation). Because dexamethasone was shown to have benefit in at least one large randomized clinical trial, patients in the backbone control arm should receive dexamethasone for a total of 10 days during the hospitalization or until or hospital discharge. Remdesivir (intravenous): 200-mg loading dose on day 1, followed by a daily maintenance dose of 100-mg on days 2 through 10. Dexamethasone (intravenous): 6 mg intravenous or oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable. |
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
|
Experimental: Imatinib + Standard of Care (CLOSED)
Subjects will be administered standard of care + 800 mg imatinib on Day 1 orally, in divided doses of 400 mg administered twice per day.
400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
|
Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days.
Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Other Names:
6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day.
400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
|
Experimental: Imatinib (PENDING ACTIVATION)
Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day.
400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
|
Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day.
400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19.
Time Frame: Up to 28 days
|
Time to reach a durable COVID-19 level 4 or less or discharge at COVID-level 4 or lower (except for discharge to another hospital), and time to death (mortality). Data will be analyzed for 3 groups:
World Health Organization 9-point ordinal scale: 0. No clinical or virologic evidence of infection
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: Up to 28 days
|
|
Up to 28 days
|
Health care utilization
Time Frame: Up to 28 days
|
Ventilator-free days
|
Up to 28 days
|
Improvement in disease severity
Time Frame: Up to 60 days
|
The measure for recovery is defined as time to reach level 4 or less in the World Health Organization COVID-19 scale for at least 48 hours - without returning to high flow oxygen or intubation, or discharge at COVID level 4 or less except for discharge to another hospital. (0 being minimum and 8 being maximum) |
Up to 60 days
|
Safety: Frequency of serious AEs
Time Frame: Up to 60 days
|
All AEs will be identified and assessed for severity using the National Cancer Institute - Common Terminology Criteria for Adverse Events v5.0 which provides a grading scale for each AE listed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. |
Up to 60 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Carolyn Carolyn, MD, University of California, San Francisco
- Principal Investigator: Kathleen D Liu, MD, University of California, San Francisco
- Principal Investigator: Laura Esserman, MD, University of California, San Francisco
Publications and helpful links
General Publications
- Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
- Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeehan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD; ISPY COVID Adaptive Platform Trial Network; undefined. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. BMJ Open. 2022 Jun 6;12(6):e060664. doi: 10.1136/bmjopen-2021-060664.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dermatologic Agents
- Serotonin Agents
- Serotonin Antagonists
- Protein Kinase Inhibitors
- Antifungal Agents
- Cyclooxygenase 2 Inhibitors
- Anti-Ulcer Agents
- Anti-Allergic Agents
- Phosphodiesterase Inhibitors
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- CCR5 Receptor Antagonists
- Calcineurin Inhibitors
- Complement Inactivating Agents
- Histamine H2 Antagonists
- Phosphodiesterase 4 Inhibitors
- Bradykinin B2 Receptor Antagonists
- Bradykinin Receptor Antagonists
- Tyrosine Kinase Inhibitors
- Dexamethasone
- Celecoxib
- Imatinib Mesylate
- Famotidine
- Apremilast
- Cyclosporine
- Cyclosporins
- Remdesivir
- Cyproheptadine
- Icatibant
- Cenicriviroc
Other Study ID Numbers
- I-SPY-COVID
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Remdesivir
-
Daewoong Pharmaceutical Co. LTD.TerminatedSevere COVID-19Korea, Republic of
-
Capital Medical UniversityCancer Institute and Hospital, Chinese Academy of Medical SciencesSuspended
-
University of PecsHungarian Ministry of Innovation and Technology; HECRIN ConsortiumUnknown
-
Capital Medical UniversityTerminated
-
Gilead SciencesCompleted
-
Lisa BarrettNova Scotia Health Authority; Dalhousie UniversityActive, not recruiting
-
Copycat Sciences LLCCompleted
-
National Institute of Allergy and Infectious Diseases...PPD; University of Washington; Vanderbilt University Medical Center; Implicit BioscienceTerminatedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19)United States
-
NEAT ID FoundationGilead SciencesRecruitingCovid19Spain, Israel, France, United Kingdom, Netherlands
-
Semmelweis UniversityCompletedCovid19 | End Stage Renal Failure on DialysisHungary